×
S&P 500   3,997.02 (+1.41%)
DOW   32,234.26 (+0.96%)
QQQ   291.16 (+1.36%)
AAPL   140.52 (+0.11%)
MSFT   263.27 (+1.41%)
FB   183.64 (+1.30%)
GOOGL   2,119.48 (+0.00%)
AMZN   2,140.53 (+2.81%)
TSLA   661.70 (+5.34%)
NVDA   168.75 (+4.46%)
BABA   82.63 (+0.19%)
NIO   14.48 (-1.03%)
AMD   92.59 (+1.57%)
CGC   5.07 (+6.51%)
MU   68.16 (+2.31%)
T   21.27 (+0.52%)
GE   73.51 (-1.36%)
F   12.69 (+2.17%)
DIS   102.87 (+1.26%)
AMC   11.53 (+10.97%)
PFE   53.68 (+0.51%)
PYPL   79.72 (+1.36%)
NFLX   186.19 (+3.24%)
S&P 500   3,997.02 (+1.41%)
DOW   32,234.26 (+0.96%)
QQQ   291.16 (+1.36%)
AAPL   140.52 (+0.11%)
MSFT   263.27 (+1.41%)
FB   183.64 (+1.30%)
GOOGL   2,119.48 (+0.00%)
AMZN   2,140.53 (+2.81%)
TSLA   661.70 (+5.34%)
NVDA   168.75 (+4.46%)
BABA   82.63 (+0.19%)
NIO   14.48 (-1.03%)
AMD   92.59 (+1.57%)
CGC   5.07 (+6.51%)
MU   68.16 (+2.31%)
T   21.27 (+0.52%)
GE   73.51 (-1.36%)
F   12.69 (+2.17%)
DIS   102.87 (+1.26%)
AMC   11.53 (+10.97%)
PFE   53.68 (+0.51%)
PYPL   79.72 (+1.36%)
NFLX   186.19 (+3.24%)
S&P 500   3,997.02 (+1.41%)
DOW   32,234.26 (+0.96%)
QQQ   291.16 (+1.36%)
AAPL   140.52 (+0.11%)
MSFT   263.27 (+1.41%)
FB   183.64 (+1.30%)
GOOGL   2,119.48 (+0.00%)
AMZN   2,140.53 (+2.81%)
TSLA   661.70 (+5.34%)
NVDA   168.75 (+4.46%)
BABA   82.63 (+0.19%)
NIO   14.48 (-1.03%)
AMD   92.59 (+1.57%)
CGC   5.07 (+6.51%)
MU   68.16 (+2.31%)
T   21.27 (+0.52%)
GE   73.51 (-1.36%)
F   12.69 (+2.17%)
DIS   102.87 (+1.26%)
AMC   11.53 (+10.97%)
PFE   53.68 (+0.51%)
PYPL   79.72 (+1.36%)
NFLX   186.19 (+3.24%)
S&P 500   3,997.02 (+1.41%)
DOW   32,234.26 (+0.96%)
QQQ   291.16 (+1.36%)
AAPL   140.52 (+0.11%)
MSFT   263.27 (+1.41%)
FB   183.64 (+1.30%)
GOOGL   2,119.48 (+0.00%)
AMZN   2,140.53 (+2.81%)
TSLA   661.70 (+5.34%)
NVDA   168.75 (+4.46%)
BABA   82.63 (+0.19%)
NIO   14.48 (-1.03%)
AMD   92.59 (+1.57%)
CGC   5.07 (+6.51%)
MU   68.16 (+2.31%)
T   21.27 (+0.52%)
GE   73.51 (-1.36%)
F   12.69 (+2.17%)
DIS   102.87 (+1.26%)
AMC   11.53 (+10.97%)
PFE   53.68 (+0.51%)
PYPL   79.72 (+1.36%)
NFLX   186.19 (+3.24%)
NASDAQ:ONCS

OncoSec Medical (ONCS) Stock Forecast, Price & News

$0.81
-0.01 (-1.80%)
(As of 05/25/2022 01:04 PM ET)
Add
Compare
Today's Range
$0.80
$0.82
50-Day Range
$0.70
$1.38
52-Week Range
$0.67
$4.25
Volume
440 shs
Average Volume
108,581 shs
Market Capitalization
$31.68 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
2.03
30 days | 90 days | 365 days | Advanced Chart
Receive ONCS News and Ratings via Email

Sign-up to receive the latest news and ratings for OncoSec Medical and its competitors with MarketBeat's FREE daily newsletter.

OncoSec Medical logo

About OncoSec Medical

OncoSec Medical Incorporated, a late-stage immuno-oncology company, focuses on designing, developing, commercializing intra-tumoral DNA-based therapeutics to stimulate and augment anti-tumor immune responses for the treatment of cancer. The company's lead product candidate is ImmunoPulse IL-12 that uses electroporation device to deliver a DNA-encoded interleukin-12 for reversing the immunosuppressive microenvironment in the treated tumor. It is also developing ImmunoPulse IL-12 with KEYTRUDA in patients with advanced melanoma that is in clinical trials collaboration and supply agreement (KEYNOTE-695) and metastatic triple negative breast cancer, which is in Phase II clinical trials (KEYNOTE-890); ImmunoPulse IL-12 and KEYTRUDA in patients with advanced or metastatic melanoma that has completed Phase II clinical trials; and ImmunoPulse IL-12 monotherapy in patients with metastatic melanoma, which has completed the Phase II clinical trials. In addition, the company is developing monotherapy biomarker study in patients with advanced or metastatic TNBC that has completed the Phase II clinical trials; and technology to treat liver, lung, bladder, pancreatic, and other visceral lesions. OncoSec Medical Incorporated has clinical trial collaborations with Merck & Co., Inc. and its subsidiary in connection with the KEYNOTE-695 and KEYNOTE-890 studies; a research collaboration with Duke University's Center for Applied Therapeutics to evaluate TAVO in combination or sequenced with a HER2-plasmid vaccine; a research collaboration with Roswell Park Comprehensive Cancer Center to evaluate the use of Roswell Park's intravital microscopy and enhanced IL-12 DNA-plasmid; and collaboration with Providence Cancer Institute. The company was formerly known as NetVentory Solutions Inc. and changed its name to OncoSec Medical Incorporated in March 2011. The company was incorporated in 2008 and is headquartered in Pennington, New Jersey.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ONCS
Employees
54
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A
Book Value
$0.97 per share

Profitability

Net Income
$-45.17 million
Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
38,508,000
Market Cap
$31.68 million
Optionable
Not Optionable

Company Calendar

Last Earnings
3/15/2022
Today
5/25/2022
Next Earnings (Estimated)
6/10/2022
Fiscal Year End
7/31/2022

MarketRank

Overall MarketRank

1.79 out of 5 stars

Medical Sector

825th out of 1,420 stocks

Pharmaceutical Preparations Industry

407th out of 678 stocks

Analyst Opinion: 3.5Community Rank: 4.0Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -













OncoSec Medical (NASDAQ:ONCS) Frequently Asked Questions

Is OncoSec Medical a buy right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for OncoSec Medical in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" OncoSec Medical stock.
View analyst ratings for OncoSec Medical
or view top-rated stocks.

When is OncoSec Medical's next earnings date?

OncoSec Medical is scheduled to release its next quarterly earnings announcement on Friday, June 10th 2022.
View our earnings forecast for OncoSec Medical
.

How were OncoSec Medical's earnings last quarter?

OncoSec Medical Incorporated (NASDAQ:ONCS) posted its quarterly earnings data on Tuesday, March, 15th. The biotechnology company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by $0.14.
View OncoSec Medical's earnings history
.

When did OncoSec Medical's stock split? How did OncoSec Medical's stock split work?

OncoSec Medical's stock reverse split before market open on Tuesday, May 21st 2019. The 1-10 reverse split was announced on Monday, May 20th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Monday, May 20th 2019. An investor that had 100 shares of OncoSec Medical stock prior to the reverse split would have 10 shares after the split.

What price target have analysts set for ONCS?

1 brokers have issued twelve-month price objectives for OncoSec Medical's shares. Their forecasts range from $5.00 to $5.00. On average, they anticipate OncoSec Medical's stock price to reach $5.00 in the next twelve months. This suggests a possible upside of 521.0% from the stock's current price.
View analysts' price targets for OncoSec Medical
or view top-rated stocks among Wall Street analysts.

Who are OncoSec Medical's key executives?
OncoSec Medical's management team includes the following people:
  • Mr. Robert J. DelAversano CPA, VP of Fin. and Principal Accounting Officer & Controller (Age 50, Pay $361.18k) (LinkedIn Profile)
  • Dr. Robert H. Arch Ph.D., Pres & CEO
  • Mr. George Chi C.F.A., CPA, Chief Financial Officer (Age 52)
  • Dr. Kim Jaffe, Assistant VP of Bus. Devel. & Operations
  • Mr. Tu Diep M.Sc., Sr. VP & Head of Operations
  • Dr. Sandra Aung Ph.D., Sr. VP & Chief Clinical Devel. Officer
  • Dr. Mai Hope Le M.D., Consultant (Age 46)
What is Punit Dhillon's approval rating as OncoSec Medical's CEO?

2 employees have rated OncoSec Medical CEO Punit Dhillon on Glassdoor.com. Punit Dhillon has an approval rating of 50% among OncoSec Medical's employees. This puts Punit Dhillon in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of OncoSec Medical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other OncoSec Medical investors own include Cytokinetics (CYTK), Inovio Pharmaceuticals (INO), XOMA (XOMA), Anavex Life Sciences (AVXL), Walt Disney (DIS), Idera Pharmaceuticals (IDRA), Sorrento Therapeutics (SRNE), Amarin (AMRN), Dynavax Technologies (DVAX) and Trevena (TRVN).

What is OncoSec Medical's stock symbol?

OncoSec Medical trades on the NASDAQ under the ticker symbol "ONCS."

Who are OncoSec Medical's major shareholders?

OncoSec Medical's stock is owned by a number of institutional and retail investors. Top institutional investors include Bank of New York Mellon Corp (0.98%), Salzhauer Michael (0.75%), Renaissance Technologies LLC (0.12%), Sandbox Financial Partners LLC (0.07%), Simplex Trading LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Company insiders that own OncoSec Medical stock include Alpha Holdings, Inc, Brian A Leuthner, Daniel J O'connor, Grand Pharmaceutical & H China, Robert J Delaversano, Robert J Delaversano and Yuhang Zhao.
View institutional ownership trends for OncoSec Medical
.

Which institutional investors are selling OncoSec Medical stock?

ONCS stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Sandbox Financial Partners LLC, Salzhauer Michael, and Simplex Trading LLC. Company insiders that have sold OncoSec Medical company stock in the last year include Brian A Leuthner, and Robert J Delaversano.
View insider buying and selling activity for OncoSec Medical
or view top insider-selling stocks.

Which institutional investors are buying OncoSec Medical stock?

ONCS stock was acquired by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp. Company insiders that have bought OncoSec Medical stock in the last two years include Grand Pharmaceutical & H China, and Yuhang Zhao.
View insider buying and selling activity for OncoSec Medical
or or view top insider-buying stocks.

How do I buy shares of OncoSec Medical?

Shares of ONCS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is OncoSec Medical's stock price today?

One share of ONCS stock can currently be purchased for approximately $0.81.

How much money does OncoSec Medical make?

OncoSec Medical has a market capitalization of $31.68 million. The biotechnology company earns $-45.17 million in net income (profit) each year or ($1.04) on an earnings per share basis.

How many employees does OncoSec Medical have?

OncoSec Medical employs 54 workers across the globe.

What is OncoSec Medical's official website?

The official website for OncoSec Medical is www.oncosec.com.

How can I contact OncoSec Medical?

OncoSec Medical's mailing address is 3565 GENERAL ATOMICS COURT, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at (858) 662-6732, via email at [email protected], or via fax at 858-430-3832.

This page was last updated on 5/25/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.